| Mental Health

MagicMed: Moving from Mental Illness to Mental Health

There has been a resurgence of interest in psychedelics as researchers look to create alternative treatment solutions for a growing patient base.

Early clinical results, increased corporate and media support and a regulatory thaw of these Schedule I compounds have created the perfect framework for the industry to benefit from what psychedelics have to offer.

In the last few years, classic psychedelics have shown the potential to provide an improved, alternative treatment solution to a vast array of mental health indications - ranging from treatment-resistant depression and anxiety to PTSD.

MagicMed: Your Partner in Biotechnology

MagicMed Industries is dedicated to being a part of the solution.

MagicMed's focus is on the development of the world's foremost library of psychedelic derivatives, called the Psybrary™.

With a vast library of individual molecules covered by several different chemical compound categories, MagicMed is pursuing partnerships with innovators in the industry to develop newly patented products

These products will help tailor drug candidates to patients' needs and unlock the healing power of psychedelics.

MagicMed has finished it's initial derivative portfolio based on the structures of psilocybin and N,N-dimethyltryptamine (DMT). Research efforts continue to create additional patents and derivative portfolios based on MDMA, mescaline, LSD and ibogaine.

| The Science:

The Impact of Psychedelic Molecules

The scientific community is paying attention to the breakthrough potential of psychedelics.

Numerous studies by institutions including Johns HopkinsUC Berkley, Imperial College, Heffter Research Institute, University of Toronto, and University of British Columbia have been investigating the benefits of therapy using psychedelics.

Building on these promising results, psychedelic pharmaceuticals need to be modified to have fewer side effects, better efficacy, and out of clinic applicability. 

The Psybrary™

The Psybrary™ is set to contain a vast portfolio of psychedelic derivatives based on the structures of psilocybin, DMT, LSD, mescaline, ibogaine and MDMA.

Designed to be the leading provider of novel drug candidates for the biotechnology and pharmaceutical industries

Combining synthetic biology and chemistry enables the largest, most diverse portfolio of psychedelic derivatives possible

Extensive, robust patenting covers compositions, manufacturing, and uses for millions of possible drug candidates

PsyAI™

PsyAI is a tool designed to streamline pharmaceutical design by predicting structure, manufacturing capabilities and pharmacological effects in an effort to accelerate the modernization of psychedelic medicine. 

Given the volume of data that will be generated at various levels including compound, test results and patient profile, the use of PsyAI will be a critical tool to process that data and generate actionable insights for the psychedelic drug development process. 

Each PsyAI module that is developed increases the value of a compound as a potential therapeutic by leveraging AI systems to reduce the time and cost of commercial development

| Investing in Mental Health

Market Potential of Psychedelic Derivatives

Psychedelics have immense potential to treat several illnesses. Multiple psychedelic-based scientific studies and clinical trials have shown promising data to treat many mental health indications.

This includes diseases and disorders such as:

  • Substance Abuse Disorders (SUDs)/Addiction
  • Alzheimer's
  • Anxiety
  • Depression
  • Anorexia Nervosa
  • Attention Deficit Hyperactivity Disorder (ADHD)
  • Obsessive-Compulsive Disorder (OCD)
  • Post-Traumatic Stress Disorder (PTSD)
  • Post-Treatment Lyme Disease Syndrome (Formerly Known as Chronic Lyme Disease)
  • Social Anxiety in Autistic Adults
  • Suicidal Ideation

What Makes MagicMed Unique

Multiple Indications

Patented molecules can address multiple psychological indications

Various Psychedelics

MagicMed has filed patents in psilocybin/N.N-dimethyltryptamine (DMT) derivatives and will expand to other psychedelics

Complementary

Platform play for the industry that does not cannibalize on sector market share

De-Risked Revenue Model with Blue Sky Royalty Potential

Revenue across the drug development stages with diversified upside potential

Multiple Partnerships

Licensing deals can be done with multiple partners

Conservative Capital Markets Strategy

Designed to be quickly cash flow positive and to come to market for capital only upon accretive or transformative events

Learn More About MagicMed

The Global Mental Illness Market

Addiction

$42 Billionª

ADHD

$9.1 Billion*

Anxiety

$4.5 Billion*

Depression

$4.0 Billion*

In-Clinic

  • Classic psychedelics administered
  • One on one treatment with trained professional
  • Single treatment session can take hours
  • Adverse side effects such as “bad trips”
  • Not accessible for majority of patients

According to IQVIA’s 2020 global annual sales report and addiction review, the annual global drug sales and treatment market for Addiction, Anxiety, Depression and ADHD are approximately $59 billion alone.

Notes: Figures are in USD. ª IQVIA Global Annual Sales Report (IQVIA, 2020). * Opioid Addiction (Azadfard M, Huecker MR, Leaming JM, 2020)

Out-Patient

  • Derivatized molecules designed from classic psychedelics
  • Accessible to a larger patient population
  • Treatment of a wider range of mental health indications
  • Specifically designed to be more effective in targeting mental health indications
  • Extensive research & development, pre-clinical and clinical trials for efficacy
  • Enhanced safety profile
  • Everyday use applicability
  • Potential to be more effective than treatments currently on the market
  • Out-patient use

| News

MagicMed Industries Announces the Establishment of Psilocybin-Derivatives Portfolio and Launch of Candidate Selection Program

MagicMed announced today that it has completed the establishment of the psilocybin-derivatives patent portfolio of the PsybraryTM and the launch of the Candidate Selection program..

Find out what MagicMed is doing to bring psychedelics to mainstream therapy

A Team Approach to Creating Novel Psychedelic-Based Treatments

There has been significant interest in the psychedelic space and of the promise psychedelic molecules show in treating mental health conditions. 

Current mental health treatment regimes are not a solution for everyone. Psychedelics offer a potential alternative treatments by acting via different mechanisms. 

Further work is required to create novel drugs that have fewer side effects, better efficacy, and out of clinic applicability. 

MagicMed Industries Inc. is working to provide this solution.

CSE: MGIC (Reserved)

Your Partner in Psychedelic Medicinals

© 2020 MagicMed Industries. All rights reserved